Market revenue in 2022 | USD 735.8 million |
Market revenue in 2030 | USD 1,108.8 million |
Growth rate | 5.3% (CAGR from 2022 to 2030) |
Largest segment | Branded |
Fastest growing segment | Generics |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Branded, Generics |
Key market players worldwide | AbbVie Inc, AstraZeneca PLC, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Bayer AG, Abbott Laboratories, Janssen Pharmaceuticals, Sun Pharmaceutical Industries, Cipla Ltd DR, Gilead Sciences Inc, Biogen Inc, Organon & Co Ordinary Shares |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to gastrointestinal therapeutics market will help companies and investors design strategic landscapes.
Branded was the largest segment with a revenue share of 68.74% in 2022. Horizon Databook has segmented the Australia gastrointestinal therapeutics market based on branded, generics covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia gastrointestinal therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into Australia gastrointestinal therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account